19:04:41 Europe / Stockholm

Bifogade filer

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Kalender

2024-11-29 Kvartalsrapport 2024-Q3
2024-08-30 Kvartalsrapport 2024-Q2
2024-05-31 Kvartalsrapport 2024-Q1
2024-05-29 Ordinarie utdelning POLAR 0.00 SEK
2024-05-28 Årsstämma 2024
2024-02-23 Bokslutskommuniké 2023
2023-11-24 Kvartalsrapport 2023-Q3
2023-09-08 Extra Bolagsstämma 2023
2023-08-25 Kvartalsrapport 2023-Q2
2023-05-26 Kvartalsrapport 2023-Q1
2023-05-17 Årsstämma 2023
2023-05-05 Ordinarie utdelning POLAR 0.00 SEK
2023-03-13 Extra Bolagsstämma 2022
2023-02-24 Bokslutskommuniké 2022
2022-11-25 Kvartalsrapport 2022-Q3
2022-08-26 Kvartalsrapport 2022-Q2
2022-05-27 Kvartalsrapport 2022-Q1
2022-05-06 Ordinarie utdelning POLAR 0.00 SEK
2022-05-05 Årsstämma 2022
2022-02-25 Bokslutskommuniké 2021
2021-11-26 Kvartalsrapport 2021-Q3
2021-08-27 Kvartalsrapport 2021-Q2
2021-05-28 Kvartalsrapport 2021-Q1
2021-05-06 Ordinarie utdelning POLAR 0.00 SEK
2021-05-05 Årsstämma 2021
2021-02-26 Bokslutskommuniké 2020
2020-11-27 Kvartalsrapport 2020-Q3
2020-08-28 Kvartalsrapport 2020-Q2
2020-07-01 Ordinarie utdelning POLAR 0.00 SEK
2020-06-30 Årsstämma 2020
2020-05-29 Kvartalsrapport 2020-Q1
2020-02-28 Bokslutskommuniké 2019
2020-02-14 Extra Bolagsstämma 2020
2019-10-23 Kvartalsrapport 2019-Q3
2019-07-24 Kvartalsrapport 2019-Q2
2019-05-07 Split POLAR 16:1
2019-04-26 Kvartalsrapport 2019-Q1
2019-03-19 Årsstämma 2019
2019-02-04 Ordinarie utdelning POLAR 0.00 SEK
2019-02-01 Bokslutskommuniké 2018

Beskrivning

LandSverige
ListaSpotlight
SektorHälsovård
IndustriMedicinteknik
Polarcool är verksamt inom medicinteknik. Idag är bolaget inriktade mot att produkter och lösningar inriktade för skador inom sport och aktivitet. Störst fokus återfinns inom forskning och utveckling av produkter som används vid behandling av hjärnskador vid exempelvis boxning, rugby och amerikansk fotboll. Verksamhet innehas på global nivå, med störst närvaro inom den europeiska marknaden.
2021-10-18 09:21:38

PolarCool AB (publ) has signed a 2-year commercial agreement with the Swiss top club HC Davos. HC Davos has evaluated the PolarCap® System and will use the system with the support of a Swiss insurance company. PolarCool's agreement with HC Davos is a rental agreement over a two-year period.

HC Davos has used the PolarCap® System during an evaluation period with a positive outcome. Together with the clinical study results in the SHL study, this has been the basis for the club's decision to sign an agreement. A large reduction of long-term absence among players treated with the PolarCap® System after a concussion, means not only medical benefits for players but also positive health effects.

The agreement could pave the way for more collaborations with other clubs in Switzerland. There are a total of twelve teams in the Swiss league National League A (NLA).

PolarCool's CEO Erik Andersson comments:

-The agreement is a breakthrough in the Swiss market. The approach with HC Davos is interesting as it means that the parties see a medical and economic value in using the PolarCap® System for the treatment of concussions.

HC Davos doctor, Dr. Walter Kistler comments:

-We are very happy, that we have this therapy option to treat hockey players effectively, so they can return to the rink faster, and also protect them from possible long-term consequences.

The agreement with HC Davos is a result of PolarCool's marketing strategy for the Swiss market. The insurance arrangements are available in various forms internationally and are interesting for PolarCool to process. Reducing the number of days of absence for athletes is positive both for the athletes themselves and the club as well as for the insurance companies.

This information is information that PolarCool (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out herein, on October 18th, 2021.